Evidence map›Paper›PMID 41249480›Full record

ArticleNature biomedical engineering2025

HBsAg-tagged tumour vaccine system eliminates solid tumours through virus-specific memory T cells.

Wenguang Wang, Ya Chu, Lili Zhao, Miao Lv, Luyao Wang, Fangfei Jin, Kaiyuan Hu, Lihang Cen, Shuang Qin, Xianjing Li and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wenguang Wang *Institute of Translational Medicine, China Pharmaceutical University, Nanjing, China. wgwang@cpu.edu.cn.ORCID http://orcid.org/0009-0009-7906-3779
Ya Chu *Institute of Translational Medicine, China Pharmaceutical University, Nanjing, China.
Lili Zhao *Institute of Translational Medicine, China Pharmaceutical University, Nanjing, China.
Miao Lv *Institute of Translational Medicine, China Pharmaceutical University, Nanjing, China.
Luyao WangInstitute of Translational Medicine, China Pharmaceutical University, Nanjing, China.
Fangfei JinInstitute of Translational Medicine, China Pharmaceutical University, Nanjing, China.
Kaiyuan HuInstitute of Translational Medicine, China Pharmaceutical University, Nanjing, China.
Lihang CenLiuzhou Municipal Liutie Central Hospital, Liuzhou, China.
Shuang QinLiuzhou Municipal Liutie Central Hospital, Liuzhou, China.
Xianjing LiInstitute of Translational Medicine, China Pharmaceutical University, Nanjing, China.ORCID http://orcid.org/0000-0002-0007-1429
Weijun ZhaoInstitute of Translational Medicine, China Pharmaceutical University, Nanjing, China. 1620144293@cpu.edu.cn.
Yiqiao HuState Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University and School of Life Sciences, Nanjing University, Nanjing, China. huyiqiao@nju.edu.cn.ORCID http://orcid.org/0000-0002-3656-7143
Shuguang ZuoLiuzhou Municipal Liutie Central Hospital, Liuzhou, China. zuosg@icloud.com.ORCID http://orcid.org/0000-0001-9649-1200
Yong YangInstitute of Translational Medicine, China Pharmaceutical University, Nanjing, China. yy@cpu.edu.cn.ORCID http://orcid.org/0000-0003-1038-9470

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82304428Natural Science Foundation of Jiangsu Province (Jiangsu Provincial Natural Science Foundation) BK20221042
6 · The paper itself

Abstract

It is challenging for cancer vaccines to identify immunogenic antigens that are specifically and uniformly expressed on heterogeneous solid tumours and that can elicit production of T cells to lyse antigen-positive tumour cells and expand within the immunosuppressive tumour microenvironment. In contrast, microbial antigens are well-defined and robustly immunogenic and can activate specific memory T cells to eliminate microbes within the tumour microenvironment. Inspired by this, we developed a hepatitis B surface antigen (HBsAg)-tagged tumour vaccine system (H-T

Identifiers

PMID41249480

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.